MCID: OPP004
MIFTS: 48

Oppositional Defiant Disorder

Categories: Mental diseases

Aliases & Classifications for Oppositional Defiant Disorder

MalaCards integrated aliases for Oppositional Defiant Disorder:

Name: Oppositional Defiant Disorder 12 76 55 6 15 73

Classifications:



External Ids:

Disease Ontology 12 DOID:0050856
ICD10 33 F91.3
UMLS 73 C0029121

Summaries for Oppositional Defiant Disorder

MalaCards based summary : Oppositional Defiant Disorder is related to depression and anxiety, and has symptoms including photophobia, restlessness and personality changes. An important gene associated with Oppositional Defiant Disorder is DRD4 (Dopamine Receptor D4), and among its related pathways/superpathways are Transmission across Chemical Synapses and Circadian entrainment. The drugs Methylphenidate and Risperidone have been mentioned in the context of this disorder. Affiliated tissues include testes, amygdala and brain, and related phenotypes are behavior/neurological and homeostasis/metabolism

Wikipedia : 76 Oppositional defiant disorder (ODD) is listed in the DSM-5 under Disruptive, impulse-control, and... more...

Related Diseases for Oppositional Defiant Disorder

Diseases related to Oppositional Defiant Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 88)
# Related Disease Score Top Affiliating Genes
1 depression 30.9 MAOA SLC6A4 TPH2
2 anxiety 30.7 COMT MAOA SLC6A4 TPH2
3 separation anxiety disorder 30.3 DRD4 SLC6A3
4 conduct disorder 30.3 COMT DBH DRD2 DRD4 MAOA SLC6A3
5 traumatic brain injury 30.1 COMT DRD2
6 brain injury 30.1 COMT DRD2
7 tic disorder 29.9 DRD2 DRD4 SLC6A3 TPH2
8 stuttering 29.9 DBH DRD2 SLC6A3
9 attention deficit-hyperactivity disorder 29.9 COMT DBH DRD2 DRD4 MAOA SLC6A2
10 borderline personality disorder 29.7 COMT MAOA SLC6A4 TPH2
11 generalized anxiety disorder 29.5 COMT DRD2 MAOA SLC6A2 SLC6A4
12 personality disorder 29.4 COMT DRD2 DRD4 MAOA SLC6A3 SLC6A4
13 gilles de la tourette syndrome 29.4 COMT DBH DRD2 DRD4 SLC6A3
14 autism 29.3 COMT DBH DRD2 DRD4 MAOA SLC6A3
15 mood disorder 29.0 COMT DRD2 DRD4 MAOA SLC6A2 SLC6A4
16 bipolar disorder 28.8 COMT DBH DRD2 DRD4 MAOA SLC6A3
17 alcohol dependence 28.6 COMT DBH DRD2 DRD4 MAOA SLC6A3
18 schizophrenia 28.4 COMT DBH DRD2 DRD4 MAOA SLC6A2
19 autism spectrum disorder 10.4
20 pseudobulbar affect 10.2
21 dependent personality disorder 10.2 DRD4 MAOA
22 avoidant personality disorder 10.1 MAOA SLC6A4
23 atypical depressive disorder 10.1 MAOA SLC6A4
24 amphetamine abuse 10.1 SLC6A2 SLC6A3
25 dysthymic disorder 10.1 MAOA SLC6A4
26 kleptomania 10.1 MAOA SLC6A4
27 delusional disorder 10.1 DRD2 DRD4
28 impulse control disorder 10.1 DRD2 DRD4
29 striatonigral degeneration 10.1 DRD2 SLC6A3
30 reading disorder 10.1
31 hematohidrosis 10.1
32 heroin dependence 10.1 DRD2 DRD4
33 phobia, specific 10.1 COMT MAOA
34 periodic limb movement disorder 10.0 DRD2 SLC6A4
35 dystonia 1, torsion, autosomal dominant 10.0 COMT MAOA
36 serotonin syndrome 10.0 MAOA SLC6A4
37 schizophreniform disorder 10.0 COMT DRD2
38 kleine-levin hibernation syndrome 10.0 COMT SLC6A3
39 polysubstance abuse 10.0 COMT DRD2
40 tardive dyskinesia 10.0 COMT DRD2
41 orofacial cleft 10.0 DRD2 DRD4 SLC6A3
42 central nervous system disease 10.0 SLC6A2 SLC6A3 SLC6A4
43 agoraphobia 10.0 MAOA SLC6A2 SLC6A4
44 restless legs syndrome 10.0 DRD2 MAOA SLC6A3
45 opiate dependence 10.0 DRD2 SLC6A4
46 fibromyalgia 10.0 COMT SLC6A4
47 opioid addiction 10.0 COMT DRD2
48 alcohol-induced mental disorder 10.0 DRD2 SLC6A3 SLC6A4
49 alcoholic psychosis 10.0 DRD2 SLC6A3 SLC6A4
50 migraine without aura 10.0 DRD2 DRD4 SLC6A4

Graphical network of the top 20 diseases related to Oppositional Defiant Disorder:



Diseases related to Oppositional Defiant Disorder

Symptoms & Phenotypes for Oppositional Defiant Disorder

UMLS symptoms related to Oppositional Defiant Disorder:


photophobia, restlessness, personality changes, pseudobulbar behavioral symptoms, sleep disturbances

MGI Mouse Phenotypes related to Oppositional Defiant Disorder:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.02 COMT DBH DRD2 DRD4 MAOA SLC6A2
2 homeostasis/metabolism MP:0005376 9.91 COMT DBH DRD2 DRD4 MAOA SLC6A2
3 cardiovascular system MP:0005385 9.87 COMT DBH DRD2 MAOA SLC6A2 SLC6A4
4 integument MP:0010771 9.63 DBH DRD2 SLC6A2 SLC6A3 SLC6A4 TPH2
5 nervous system MP:0003631 9.61 COMT DBH DRD2 DRD4 MAOA SLC6A2
6 taste/olfaction MP:0005394 8.8 DRD2 SLC6A3 TPH2

Drugs & Therapeutics for Oppositional Defiant Disorder

Drugs for Oppositional Defiant Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 69)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Methylphenidate Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 113-45-1 4158
2
Risperidone Approved, Investigational Phase 4,Phase 3 106266-06-2 5073
3
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 51-61-6, 62-31-7 681
4
Dextroamphetamine Approved, Illicit Phase 4 51-64-9 5826
5
Valproic Acid Approved, Investigational Phase 4 99-66-1 3121
6
Amphetamine Approved, Illicit, Investigational Phase 4 300-62-9 5826 3007
7
Guanfacine Approved, Investigational Phase 4 29110-47-2 3519
8
Aripiprazole Approved, Investigational Phase 4,Phase 3,Not Applicable 129722-12-9 60795
9
Olanzapine Approved, Investigational Phase 4 132539-06-1 4585
10
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
11
Bupivacaine Approved, Investigational Phase 4 2180-92-9, 38396-39-3 2474
12 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Not Applicable
13 Neurotransmitter Uptake Inhibitors Phase 4,Phase 3,Phase 2,Not Applicable
14 Dopamine Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
15 Central Nervous System Stimulants Phase 4,Phase 2,Phase 3,Not Applicable
16 Serotonin Antagonists Phase 4,Phase 3,Phase 2
17 Serotonin Agents Phase 4,Phase 3,Phase 2,Phase 1
18 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
19 Dopamine Antagonists Phase 4,Phase 3,Phase 2
20 Dopamine Uptake Inhibitors Phase 4,Phase 2,Phase 3,Not Applicable
21 Antipsychotic Agents Phase 4,Phase 3,Phase 2,Not Applicable
22 Tranquilizing Agents Phase 4,Phase 3,Phase 2,Not Applicable
23 Psychotropic Drugs Phase 4,Phase 3,Phase 2,Not Applicable
24 Anticonvulsants Phase 4
25 GABA Agents Phase 4
26 Antimanic Agents Phase 4
27 Adrenergic Agents Phase 4,Phase 3
28 Atomoxetine Hydrochloride Phase 4,Phase 3
29 Autonomic Agents Phase 4
30 Sympathomimetics Phase 4
31 Peripheral Nervous System Agents Phase 4
32 Antihypertensive Agents Phase 4
33 Adrenergic alpha-Agonists Phase 4
34 Adrenergic alpha-2 Receptor Agonists Phase 4
35 Adrenergic Agonists Phase 4
36 Insulin, Globin Zinc Phase 4
37 Gastrointestinal Agents Phase 4
38 Antiemetics Phase 4
39 Serotonin Uptake Inhibitors Phase 4
40 insulin Phase 4
41 Lisdexamfetamine Dimesylate Phase 4
42 Anesthetics, Local Phase 4
43 Anesthetics Phase 4
44
Serotonin Investigational, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1 50-67-9 5202
45
Ethanol Approved Phase 2, Phase 3 64-17-5 702
46
Pomegranate Experimental, Investigational Phase 2, Phase 3
47
2-Phenylethanol Experimental Phase 2, Phase 3 60-12-8 6054
48 Pharmaceutical Solutions Phase 3,Phase 2,Not Applicable
49 Omega 3 Fatty Acid Phase 2, Phase 3,Phase 3,Not Applicable
50 Antioxidants Phase 2, Phase 3,Phase 1

Interventional clinical trials:

(show top 50) (show all 89)
# Name Status NCT ID Phase Drugs
1 Methylphenidate vs. Risperidone for the Treatment of Children and Adolescents With ADHD and Disruptive Disorders Unknown status NCT02063945 Phase 4 Methylphenidate;Risperidone
2 Effectiveness of Combined Medication Treatment for Aggression in Children With Attention Deficit With Hyperactivity Disorder (The SPICY Study) Unknown status NCT00794625 Phase 4 Valproate;Risperidone;Placebo;Stimulant medication
3 Comparison of Atomoxetine Versus Placebo in Children and Adolescents With ADHD and Comorbid ODD in Germany Completed NCT00406354 Phase 4 Atomoxetine;Placebo
4 Medication Strategies for Treating Aggressive Behavior in Youth With Attention Deficit Hyperactivity Disorder Completed NCT00228046 Phase 4 Divalproex Sodium;Methylphenidate;Dextroamphetamine;Mixed Amphetamine Salts
5 Intuniv vs Placebo in the Treatment of Childhood Intermittent Explosive Disorder Completed NCT02048241 Phase 4 Intuniv
6 Metabolic Effects of Antipsychotics in Children Completed NCT00205699 Phase 4 risperidone;olanzapine;aripiprazole
7 A Randomized, Double-Blind Comparison of Placebo and Atomoxetine Hydrochloride Given Once a Day in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD) Completed NCT00190775 Phase 4 Atomoxetine Hydrochloride;Placebo
8 Does Pharmacological Treatment of Attention Deficit Hyperactivity Disorder (ADHD) in Adults Enhance Parenting Performance? Completed NCT01127607 Phase 4 lisdexamfetamine
9 Methylphenidate in Adults With Attention Deficit/Hyperactivity Disorder Recruiting NCT02951754 Phase 4 Immediate-release Methylphenidate
10 Neurophysiological Markers of Pediatric Irritability and Its Response to Intervention Recruiting NCT03279952 Phase 4 CNS Stimulant
11 A Multi-site Randomized Controlled Trial Comparing Regional and General Anesthesia for Effects on Neurodevelopmental Outcome and Apnea in Infants Active, not recruiting NCT00756600 Phase 4 Regional Anesthesia;General Anesthesia
12 Stimulant vs. Non-stimulant Treatments and Reward Processing in Drug-naive Youth at SUD Risk Not yet recruiting NCT03781765 Phase 4 Methylphenidate;Atomoxetine
13 Effects of Evening Dose of Immediate Release Methylphenidate on Sleep in Children With ADHD Terminated NCT02638168 Phase 4 Immediate Release Methylphenidate;Placebo
14 An Italian Study of the Efficacy of Atomoxetine in the Treatment of Children and Adolescents With Attention-Deficit/Hyperactivity Disorder (ADHD) and Comorbid Oppositional Defiant Disorder (ODD). Completed NCT00192023 Phase 3 atomoxetine 0.5 mg/kg/day;placebo;atomoxetine 1.2 mg/kg/day;atomoxetine 1.2-1.4 mg/kg/day
15 Comparison of Atomoxetine and Placebo in Children and Adolescents With ADHD and ODD Completed NCT00191698 Phase 3 atomoxetine hydrochloride;placebo
16 Treatment of Children With Peer Related Aggressive Behavior Completed NCT01406067 Phase 3
17 Strongest Families Ontario (Formerly the Family Help Program) Completed NCT01473511 Phase 3
18 A Study of the Safety and Effectiveness of Risperidone Versus Placebo for the Treatment of Conduct Disorder in Children With Mild, Moderate, or Borderline Mental Retardation Completed NCT00266552 Phase 3 risperidone
19 A Study of the Safety and Effectiveness of Risperidone for the Treatment of Conduct Disorder and Other Disruptive Behavior Disorders in Children Ages 5 to 12 With Mild, Moderate, or Borderline Mental Retardation Completed NCT00250354 Phase 3 Risperidone oral solution
20 Omega-3 Supplementation and Behavior Problems Completed NCT02334098 Phase 2, Phase 3
21 Omega-3 Supplements to Reduce Antisocial Behaviour in Young Offenders Completed NCT03627312 Phase 2, Phase 3
22 Computerized Cognitive Behavioral Therapy for Childhood Anxiety in Community Health Centers Completed NCT01416805 Phase 3
23 Study to Determine Whether There Are Any Cognitive or Motor Effects From Taking the Medicine Risperidone. Completed NCT00399698 Phase 3 Risperdal
24 A Study of Pediatric Patients With Attention Deficit/Hyperactivity Disorder Completed NCT00922636 Phase 2, Phase 3 LY2216684;Methylphenidate;Placebo (tablet);Placebo (capsule)
25 Parent Training to Promote Early Identification and Treatment of Childhood Behavioral Disorders Completed NCT00402857 Phase 3
26 Brief Strategic Family Therapy for Adolescent Drug Abusers Completed NCT00095303 Phase 3
27 Safety and Tolerability of Once-daily Oral Aripiprazole in Children and Adolescents With Tourette's Disorder Completed NCT01727713 Phase 3 Aripiprazole
28 Efficacy of Atomoxetine on Psychosocial Function of Children and Adolescents With Attention-Deficit/Hyperactivity Disorder (ADHD) Completed NCT00320528 Phase 3 atomoxetine
29 A Study of Pediatric Participants With Attention Deficit/Hyperactivity Disorder Terminated NCT00965419 Phase 2, Phase 3 Edivoxetine
30 Ziprasidone for Severe Conduct and Other Disruptive Behavior Disorders Completed NCT00676429 Phase 2 Ziprasidone Hydrochloride;Placebo
31 Home Based Treatment for Drug Use in Early Adolescents Completed NCT00280228 Phase 2
32 Quetiapine and Concerta in the Treatment for ADHD and Aggressive Behavior. Completed NCT00550147 Phase 2 Oros Methylphenidate;quetiapine
33 Placebo-Controlled Trial With GlyTI-M Among Children With Attention Deficit Hyperactivity Disorder (ADHD) Completed NCT01725737 Phase 2 GlyTI-M;Placebo
34 Oxytocin on Irritability/Emotional Dysregulation of Disruptive Behavior and Mood Disorders Recruiting NCT02824627 Phase 2 Oxytocin;Placebo
35 Evaluating the Efficacy of Supplementation With Micronutrients in ADHD Youth Recruiting NCT03252522 Phase 1, Phase 2
36 Treatment of Conduct Problems and Depression Unknown status NCT01267773 Phase 1
37 Trial to Assess the Pharmacokinetics, Safety, Tolerability of Oral Brexpiprazole in Children (6 to <13 Years Old) With Central Nervous System Disorders Completed NCT03292848 Phase 1 Brexpiprazole
38 Prevention of Oppositional Defiant and Conduct Disorders in Preschool Children Unknown status NCT00189189 Not Applicable
39 Guided Self-Help for Parents of Children With Externalizing Problem Behavior Unknown status NCT01350986 Not Applicable
40 Epidemiological Study for Psychiatric Disorder Among Children and Adolescents Unknown status NCT02707848
41 Explore the Association Between Neuropsychological Functions and ADHD Diagnosis and Comorbid Using Longitudinal Study in Preschool Children Unknown status NCT02433145
42 Toolkit for School Behavior Modification in Children With Attention-Deficit/Hyperactivity Disorder (ADHD) Unknown status NCT01330849 Not Applicable
43 Better Understand Children and Adolescents' Intrafamilial Oppositional Defiant Disorder Completed NCT03447535
44 Comparison of Two Psychosocial Therapies for Treating Children With Oppositional-Defiant Disorder Completed NCT00510120 Not Applicable
45 Multi-Family Group Therapy for Reducing Behavioral Difficulties in Youth Completed NCT00404911 Not Applicable
46 On-line Treatment for Conduct Problems Completed NCT01822392 Not Applicable
47 Behavioral Treatment for Children With Conduct Problems and Callous-Unemotional Traits Completed NCT01362946 Not Applicable
48 Prevention of Child Mental Health Problems in Southeastern Europe Completed NCT03552250 Not Applicable
49 Supplements and Social Skills Intervention Study Completed NCT00819429 Not Applicable
50 Evaluating the Feasibility of Internet-delivered PCIT Completed NCT03260725 Not Applicable

Search NIH Clinical Center for Oppositional Defiant Disorder

Genetic Tests for Oppositional Defiant Disorder

Anatomical Context for Oppositional Defiant Disorder

MalaCards organs/tissues related to Oppositional Defiant Disorder:

41
Testes, Amygdala, Brain, Eye, Thyroid, Cortex

Publications for Oppositional Defiant Disorder

Articles related to Oppositional Defiant Disorder:

(show top 50) (show all 293)
# Title Authors Year
1
The effect of methylphenidate treatment on psychopathic behavior of patients having attention-deficit hyperactivity disorder with and without oppositional defiant disorder. ( 29958238 )
2018
2
Executive Attention and Empathy-Related Responses in Boys with Oppositional Defiant Disorder or Conduct Disorder, With and Without Comorbid Anxiety Disorder. ( 29752662 )
2018
3
Junior temperament character inventory together with quantitative EEG discriminate children with attention deficit hyperactivity disorder combined subtype from children with attention deficit hyperactivity disorder combined subtype plus oppositional defiant disorder. ( 29787785 )
2018
4
Child-based treatment of oppositional defiant disorder: mediating effects on parental depression, anxiety and stress. ( 29948233 )
2018
5
Oppositional defiant disorder/conduct disorder co-occurrence increases the risk of Internet addiction in adolescents with attention-deficit hyperactivity disorder. ( 29865863 )
2018
6
Maltreatment and Affective and Behavioral Problems in Emerging Adults With and Without Oppositional Defiant Disorder Symptoms: Mediation by Parent-Child Relationship Quality. ( 29528803 )
2018
7
Impact of Drug Adherence on Oppositional Defiant Disorder and Conduct Disorder Among Patients With Attention-Deficit/Hyperactivity Disorder. ( 30192445 )
2018
8
Saliva oxytocin, cortisol, and testosterone levels in adolescent boys with autism spectrum disorder, oppositional defiant disorder/conduct disorder and typically developing individuals. ( 30201120 )
2018
9
Oppositional Defiant Disorder dimensions and aggression: The moderating role of hostile bias and sex. ( 30009747 )
2018
10
Associations of serotonin transporter gene promoter polymorphisms and monoamine oxidase A gene polymorphisms with oppositional defiant disorder in a Chinese Han population. ( 30126429 )
2018
11
Narcissistic traits and self-esteem in children: Results from a community and a clinical sample of patients with oppositional defiant disorder. ( 30142585 )
2018
12
Change in Maternal Stress for Families in Treatment for their Children with Oppositional Defiant Disorder. ( 30294196 )
2018
13
Longitudinal linkages between parenting stress and oppositional defiant disorder (ODD) symptoms among Chinese children with ODD. ( 30321015 )
2018
14
Informant-specific reports of peer and teacher relationships buffer the effects of harsh parenting on children's oppositional defiant disorder during kindergarten. ( 30458890 )
2018
15
External validation of a bifactor model of oppositional defiant disorder. ( 30538308 )
2018
16
Structural Brain Abnormalities of Attention-Deficit/Hyperactivity Disorder With Oppositional Defiant Disorder. ( 28911901 )
2017
17
Children with ADHD and symptoms of oppositional defiant disorder improved in behavior when treated with methylphenidate and adjuvant risperidone, though weight gain was also observed - Results from a randomized, double-blind, placebo-controlled clinical trial. ( 28213188 )
2017
18
The Mutual Effect of Marital Quality and Parenting Stress on Child and Parent Depressive Symptoms in Families of Children with Oppositional Defiant Disorder. ( 29104548 )
2017
19
Predictors of Partial Hospital Readmission for Young Children with Oppositional Defiant Disorder. ( 29164350 )
2017
20
Boys with Oppositional Defiant Disorder/Conduct Disorder Show Impaired Adaptation During Stress: An Executive Functioning Study. ( 28755013 )
2017
21
The Possible Effect of Methylphenidate Treatment on Empathy in Children Diagnosed with Attention-Deficit/Hyperactivity Disorder, Both With and Without Comorbid Oppositional Defiant Disorder. ( 28398816 )
2017
22
Sex differences in the associations between vagal reactivity and oppositional defiant disorder symptoms. ( 28573761 )
2017
23
The Characteristics and Age Effects of Emotional Lability in ADHD Children With and Without Oppositional Defiant Disorder. ( 29224418 )
2017
24
Family and Individual Risk and Protective Factors of Depression among Chinese Migrant Children with Oppositional Defiant Disorder Symptoms. ( 28421024 )
2017
25
Age 4 Predictors of Oppositional Defiant Disorder in Early Grammar School. ( 28278601 )
2017
26
Parental involvement as an etiological moderator of middle childhood oppositional defiant disorder. ( 28263622 )
2017
27
Neurobiological stress responses predict aggression in boys with oppositional defiant disorder/conduct disorder: a 1-year follow-up intervention study. ( 28181041 )
2017
28
Comparing the characteristics and outcomes of parent- and teacher-reported oppositional defiant disorder: findings from a national sample. ( 29230806 )
2017
29
Oppositional defiant disorder: current insight. ( 29238235 )
2017
30
Multi-Level Family Factors and Affective and Behavioral Symptoms of Oppositional Defiant Disorder in Chinese Children. ( 28713321 )
2017
31
Is emotional dysregulation a risk indicator for auto-aggression behaviors in adolescents with oppositional defiant disorder? ( 27764737 )
2017
32
Oppositional defiant disorder dimensions: genetic influences and risk for later psychopathology. ( 28059443 )
2017
33
A Naturalistic Comparison of Methylphenidate and Risperidone Monotherapy in Drug-Naive Youth With Attention-Deficit/Hyperactivity Disorder Comorbid With Oppositional Defiant Disorder and Aggression. ( 28806385 )
2017
34
Risk factors for comorbid oppositional defiant disorder in attention-deficit/hyperactivity disorder. ( 28283834 )
2017
35
Testing Multiple Conceptualizations of Oppositional Defiant Disorder in Youth. ( 28287828 )
2017
36
Executive Function Features in Drug-naive Children with Oppositional Defiant Disorder. ( 28955142 )
2017
37
Effect of Methylphenidate on Emotional Dysregulation in Children With Attention-Deficit/Hyperactivity Disorder + Oppositional Defiant Disorder/Conduct Disorder. ( 28225747 )
2017
38
Emotional Abilities in Children with Oppositional Defiant Disorder (ODD): Impairments in Perspective-Taking and Understanding Mixed Emotions are Associated with High Callous-Unemotional Traits. ( 27100725 )
2017
39
Predicting Depression and Anxiety from Oppositional Defiant Disorder Symptoms in Elementary School-Age Girls and Boys with Conduct Problems. ( 27209374 )
2017
40
Factors related to the comorbidity between oppositional defiant disorder and anxiety disorders in preschool children. ( 27575516 )
2016
41
Trait and State Variance in Oppositional Defiant Disorder Symptoms: A Multi-Source Investigation With Spanish Children. ( 27148784 )
2016
42
Child Personality Accounts for Oppositional Defiant Disorder Comorbidity Patterns. ( 27233508 )
2016
43
Emotional Regulation and Executive Function Deficits in Unmedicated Chinese Children with Oppositional Defiant Disorder. ( 27247593 )
2016
44
Callous unemotional traits, autism spectrum disorder symptoms and empathy in boys with oppositional defiant disorder or conduct disorder. ( 27575651 )
2016
45
Sex Differences in the Prevalence of Oppositional Defiant Disorder During Middle Childhood: a Meta-Analysis. ( 27282758 )
2016
46
Common Questions About Oppositional Defiant Disorder. ( 27035043 )
2016
47
Association of tryptophan hydroxylase-2 polymorphisms with oppositional defiant disorder in a Chinese Han population. ( 27871272 )
2016
48
The Reciprocal Influence of Callous-Unemotional Traits, Oppositional Defiant Disorder and Parenting Practices in Preschoolers. ( 27013514 )
2016
49
The Longitudinal Effects of Oppositional Defiant Disorder Symptoms on Academic and Occupational Functioning in the Transition to Young Adulthood. ( 27469319 )
2016
50
Innocent or Intentional?: Interpreting Oppositional Defiant Disorder in a Preschool Mental Health Clinic. ( 27761690 )
2016

Variations for Oppositional Defiant Disorder

Expression for Oppositional Defiant Disorder

Search GEO for disease gene expression data for Oppositional Defiant Disorder.

Pathways for Oppositional Defiant Disorder

Pathways related to Oppositional Defiant Disorder according to GeneCards Suite gene sharing:

(show all 18)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.71 COMT MAOA SLC6A3 SLC6A4
2
Show member pathways
12.7 COMT DRD2 DRD4 MAOA SLC6A3
3 12.29 COMT DBH TPH2
5 11.92 MAOA SLC6A4 TPH2
6 11.86 SLC6A2 SLC6A3 SLC6A4
7
Show member pathways
11.72 DRD2 MAOA SLC6A3
8 11.69 MAOA SLC6A4 TPH2
9
Show member pathways
11.47 COMT DBH MAOA
10
Show member pathways
11.4 COMT SLC6A2 SLC6A4
11
Show member pathways
11.17 DBH TPH2
12 10.91 DBH SLC6A2
13 10.88 MAOA SLC6A4 TPH2
14
Show member pathways
10.73 DBH MAOA SLC6A2 SLC6A3 SLC6A4 TPH2
15
Show member pathways
10.69 COMT MAOA
16
Show member pathways
10.67 COMT DBH MAOA
17
Show member pathways
10.67 COMT MAOA SLC6A3 SLC6A4
18 10.64 COMT MAOA

GO Terms for Oppositional Defiant Disorder

Cellular components related to Oppositional Defiant Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integral component of membrane GO:0016021 9.92 COMT DBH DRD2 DRD4 MAOA SLC6A2
2 integral component of plasma membrane GO:0005887 9.77 DRD2 DRD4 SLC6A2 SLC6A3 SLC6A4
3 membrane raft GO:0045121 9.58 SLC6A2 SLC6A3 SLC6A4
4 neuron projection GO:0043005 9.46 SLC6A2 SLC6A3 SLC6A4 TPH2
5 dopaminergic synapse GO:0098691 9.26 DRD2 SLC6A3
6 integral component of presynaptic membrane GO:0099056 9.13 DRD2 SLC6A3 SLC6A4
7 integral component of postsynaptic membrane GO:0099055 8.8 DRD2 SLC6A3 SLC6A4

Biological processes related to Oppositional Defiant Disorder according to GeneCards Suite gene sharing:

(show all 32)
# Name GO ID Score Top Affiliating Genes
1 chemical synaptic transmission GO:0007268 9.81 DBH DRD4 SLC6A2
2 response to drug GO:0042493 9.72 COMT DRD2 SLC6A2 SLC6A3 SLC6A4
3 locomotory behavior GO:0007626 9.69 DBH DRD2 SLC6A3
4 social behavior GO:0035176 9.65 DRD4 SLC6A4
5 visual learning GO:0008542 9.65 DBH DRD2
6 response to cocaine GO:0042220 9.65 DRD2 SLC6A3
7 response to nicotine GO:0035094 9.64 DRD2 SLC6A3
8 positive regulation of multicellular organism growth GO:0040018 9.63 DRD2 SLC6A3
9 associative learning GO:0008306 9.63 DBH DRD2
10 arachidonic acid secretion GO:0050482 9.62 DRD2 DRD4
11 behavioral response to cocaine GO:0048148 9.62 DRD2 DRD4
12 dopamine receptor signaling pathway GO:0007212 9.61 DRD2 DRD4
13 negative regulation of protein secretion GO:0050709 9.61 DRD2 DRD4
14 neurotransmitter transport GO:0006836 9.61 SLC6A2 SLC6A3 SLC6A4
15 response to iron ion GO:0010039 9.6 DRD2 SLC6A3
16 prepulse inhibition GO:0060134 9.59 DRD2 SLC6A3
17 neurotransmitter biosynthetic process GO:0042136 9.58 SLC6A3 SLC6A4
18 adenylate cyclase-inhibiting dopamine receptor signaling pathway GO:0007195 9.58 DRD2 DRD4
19 response to amphetamine GO:0001975 9.58 DBH DRD2 DRD4
20 catecholamine metabolic process GO:0006584 9.57 COMT MAOA
21 neurotransmitter catabolic process GO:0042135 9.56 COMT MAOA
22 regulation of dopamine metabolic process GO:0042053 9.55 DRD4 SLC6A3
23 adenohypophysis development GO:0021984 9.54 DRD2 SLC6A3
24 response to pain GO:0048265 9.54 COMT DBH SLC6A2
25 negative regulation of voltage-gated calcium channel activity GO:1901386 9.52 DRD2 DRD4
26 fear response GO:0042596 9.49 DBH DRD4
27 positive regulation of dopamine uptake involved in synaptic transmission GO:0051586 9.48 DRD2 DRD4
28 response to histamine GO:0034776 9.46 DRD2 DRD4
29 dopamine metabolic process GO:0042417 9.43 COMT DRD2 DRD4
30 behavioral response to ethanol GO:0048149 9.33 DBH DRD2 DRD4
31 monoamine transport GO:0015844 9.13 SLC6A2 SLC6A3 SLC6A4
32 dopamine catabolic process GO:0042420 8.92 COMT DBH MAOA SLC6A3

Molecular functions related to Oppositional Defiant Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 symporter activity GO:0015293 9.61 SLC6A2 SLC6A3 SLC6A4
2 drug binding GO:0008144 9.54 DRD2 DRD4 SLC6A3
3 dopamine neurotransmitter receptor activity, coupled via Gi/Go GO:0001591 9.4 DRD2 DRD4
4 neurotransmitter:sodium symporter activity GO:0005328 9.33 SLC6A2 SLC6A3 SLC6A4
5 dopamine neurotransmitter receptor activity GO:0004952 9.32 DRD2 DRD4
6 dopamine:sodium symporter activity GO:0005330 9.26 SLC6A2 SLC6A3
7 dopamine binding GO:0035240 9.13 DRD2 DRD4 SLC6A3
8 monoamine transmembrane transporter activity GO:0008504 8.8 SLC6A2 SLC6A3 SLC6A4
9 metal ion binding GO:0046872 10 COMT DBH DRD4 SLC6A2 SLC6A3 SLC6A4

Sources for Oppositional Defiant Disorder

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....